Philip E Castle1, Julia C Gage, Cosette M Wheeler, Mark Schiffman. 1. From the American Society for Clinical Pathology Institute, Washington, DC; the Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; and the Department of Pathology, University of New Mexico Health Sciences Center, School of Medicine, Albuquerque, New Mexico.
Abstract
OBJECTIVE: To determine whether the diagnosis of cervical intraepithelial neoplasia (CIN) grade 1 increases the risk of CIN 3 above what is observed for human papillomavirus (HPV) infection. METHODS: Using data from the atypical squamous cells of undetermined significance (ASCUS) and low-grade squamous intraepithelial lesions (LSIL) triage study, we compared the 2-year cumulative risk of CIN 3 for women with an enrollment diagnosis of CIN 1 (n=594) (median age 23 years) compared with those with negative histology or no biopsy taken at colposcopy ("no CIN 1," n=570) (median age 24 years). Baseline cervical specimens were tested for carcinogenic HPV by a clinical HPV test and HPV genotypes by polymerase chain reaction. Logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) as a measure of association of enrollment status, including CIN 1 compared with no CIN 1 diagnosis, with 2-year worst outcomes of CIN 3. RESULTS: The two-year risks of CIN 3 were 10.3% (95% CI 7.9-13.0) for women with CIN 1, 7.3% (95% CI 4.6-10.9) for negative histology, and 6.4% (95% CI 3.8-9.9) for women referred to colposcopy and no biopsies were taken (P=.1). The 2-year risks of CIN 3 for women positive for HPV16, HPV18, or other carcinogenic HPV genotypes were 19.1%, 13.9%, and 5.7%, respectively, and did not differ significantly by the baseline cytology interpretation (ASCUS or LSIL). Taking HPV genotypes into account, having a CIN 1 (compared with no CIN 1) was not a risk factor for developing CIN 3 (OR 0.99, 95% CI 0.54-1.8). CONCLUSION: A CIN 1 diagnosis does not represent a significant risk factor for CIN 3 above the risk attributed to its molecular cause, genotype-specific HPV infection. LEVEL OF EVIDENCE: II.
OBJECTIVE: To determine whether the diagnosis of cervical intraepithelial neoplasia (CIN) grade 1 increases the risk of CIN 3 above what is observed for humanpapillomavirus (HPV) infection. METHODS: Using data from the atypical squamous cells of undetermined significance (ASCUS) and low-grade squamous intraepithelial lesions (LSIL) triage study, we compared the 2-year cumulative risk of CIN 3 for women with an enrollment diagnosis of CIN 1 (n=594) (median age 23 years) compared with those with negative histology or no biopsy taken at colposcopy ("no CIN 1," n=570) (median age 24 years). Baseline cervical specimens were tested for carcinogenic HPV by a clinical HPV test and HPV genotypes by polymerase chain reaction. Logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) as a measure of association of enrollment status, including CIN 1 compared with no CIN 1 diagnosis, with 2-year worst outcomes of CIN 3. RESULTS: The two-year risks of CIN 3 were 10.3% (95% CI 7.9-13.0) for women with CIN 1, 7.3% (95% CI 4.6-10.9) for negative histology, and 6.4% (95% CI 3.8-9.9) for women referred to colposcopy and no biopsies were taken (P=.1). The 2-year risks of CIN 3 for women positive for HPV16, HPV18, or other carcinogenic HPV genotypes were 19.1%, 13.9%, and 5.7%, respectively, and did not differ significantly by the baseline cytology interpretation (ASCUS or LSIL). Taking HPV genotypes into account, having a CIN 1 (compared with no CIN 1) was not a risk factor for developing CIN 3 (OR 0.99, 95% CI 0.54-1.8). CONCLUSION: A CIN 1 diagnosis does not represent a significant risk factor for CIN 3 above the risk attributed to its molecular cause, genotype-specific HPV infection. LEVEL OF EVIDENCE: II.
Authors: Julia C Gage; Mark Schiffman; William C Hunt; Nancy Joste; Arpita Ghosh; Nicolas Wentzensen; Cosette M Wheeler Journal: Am J Clin Pathol Date: 2013-03 Impact factor: 2.493
Authors: Belinda Nedjai; Caroline Reuter; Amar Ahmad; Rawinder Banwait; Rhian Warman; James Carton; Sabrina Boer; Jack Cuzick; Attila T Lorincz Journal: Int J Cancer Date: 2018-07-03 Impact factor: 7.396
Authors: Yung Taek Ouh; Ji Jeong Park; Minjoo Kang; Miseon Kim; Jae Yun Song; So Jin Shin; Seung Hyuk Shim; Heon Jong Yoo; Maria Lee; Sung Jong Lee; Whan Shin; Gun Oh Chong; Min Chul Choi; Chel Hun Choi; Kyung Jin Min Journal: J Korean Med Sci Date: 2021-06-21 Impact factor: 2.153